Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance

Molecular Immunology

Volumn 56, Issue 1-2, 2013, Pages 104-112

  Liu, Dan ^a   Shi, Ming ^b   Duan, Chenyang ^c   Chen, Hongyu ^b   Hu, Yabin ^b   Yang, Zhengyan ^b   Duan, Huijun ^a   Guo, Ning ^b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

AKT; Breast cancer; Cell migration; Erbin; Her2; Trastuzumab resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBIN PROTEIN; NEU DIFFERENTIATION FACTOR; PICTILISIB; PROTEIN KINASE B; REGULATOR PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; ERBIN; PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INDUCTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR INVASION; CHEMOSENSITIZATION; CONCENTRATION (PARAMETERS); ENZYME PHOSPHORYLATION; FEMALE;

EID: 84879162168     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.04.007     Document Type: Article

References (38)

1. Arteaga C.L., Sliwkowski M.X., Osborne C.K., Perez E.A., Puglisi F., Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nature Reviews Clinical Oncology 2012, 9:16-32.
2. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer 2009, 9:463-475.
3. Bilder D., Birnbaum D., Borg J.P., Bryant P., Huigbretse J., Jansen E., Kennedy M.B., Labouesse M., Legouis R., Mechler B., Perrimon N., Petit M., Sinha P. Collective nomenclature for LAP proteins. Nature Cell Biology 2000, 2:E114.
4. Borg J.P., Marchetto S., Le Bivic A., Ollendorff V., Jaulin-Bastard F., Saito H., Fournier E., Adelaide J., Margolis B., Birnbaum D. ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nature Cell Biology 2000, 2:407-414.
5. Bossinger O., Fukushige T., Claeys M., Borgonie G., McGhee J.D. The apical disposition of the Caenorhabditis elegans intestinal terminal web is maintained by LET-413. Developmental Biology 2004, 268:448-456.
6. Dai P., Xiong W.C., Mei L. Erbin inhibits RAF activation by disrupting the sur-8-Ras-Raf complex. Journal of Biological Chemistry 2006, 281:927-933.
7. Dan L., Shi M., Duan H., Han C., Guo N. Erbin, a negative regulator in diverse signal pathways. Current Protein and Peptide Science 2010, 11:759-764.
8. Dillon C., Creer A., Kerr K., Kumin A., Dickson C. Basolateral targeting of ERBB2 is dependent on a novel bipartite juxtamembrane sorting signal but independent of the C-terminal ERBIN-binding domain. Molecular and Cellular Biology 2002, 22:6553-6563.
9. Ellenbroek S.I., Iden S., Collard J.G. Cell polarity proteins and cancer. Seminars in Cancer Biology 2012, 22:208-215.
10. Elsum I., Yates L., Humbert P.O., Richardson H.E. The Scribble-Dlg-Lgl polarity module in development and cancer: from flies to man. Essays in Biochemistry 2012, 53:141-168.
11. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Reviews Cancer 2009, 9:550-562.
12. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Kofler M., Jorissen R.N., Nice E.C., Burgess A.W., Ward C.W. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Molecular Cell 2003, 11:495-505.
13. Huang Y.Z., Wang Q., Xiong W.C., Mei L. Erbin is a protein concentrated at postsynaptic membranes that interacts with PSD-95. Journal of Biological Chemistry 2001, 276:19318-19326.
14. Huang Y.Z., Zang M., Xiong W.C., Luo Z., Mei L. Erbin suppresses the MAP kinase pathway. Journal of Biological Chemistry 2003, 278:1108-1114.
15. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer 2005, 5:341-354.
16. Hynes N.E., MacDonald G. ErbB receptors and signaling pathways in cancer. Current Opinion in Cell Biology 2009, 21:177-184.
17. Izawa I., Nishizawa M., Tomono Y., Ohtakara K., Takahashi T., Inagaki M. ERBIN associates with p0071, an armadillo protein, at cell-cell junctions of epithelial cells. Genes to Cells 2002, 7:475-485.
18. Jaulin-Bastard F., Arsanto J.P., Le Bivic A., Navarro C., Vely F., Saito H., Marchetto S., Hatzfeld M., Santoni M.J., Birnbaum D., Borg J.P. Interaction between Erbin and a Catenin-related protein in epithelial cells. Journal of Biological Chemistry 2002, 277:2869-2875.
19. Jaulin-Bastard F., Saito H., Le Bivic A., Ollendorff V., Marchetto S., Birnbaum D., Borg J.P. The ERBB2/HER2 receptor differentially interacts with ERBIN and PICK1 PSD-95/DLG/ZO-1 domain proteins. Journal of Biological Chemistry 2001, 276:15256-15263.
20. Junttila T.T., Akita R.W., Parsons K., Fields C., Lewis Phillips G.D., Friedman L.S., Sampath D., Sliwkowski M.X. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440.
21. Kolch W. Erbin: Sorting out ErbB2 Receptors or Giving Ras a Break? 2003, pe37, Sci. STKE. 10.1126/scisignal.1992003pe37.
22. Legouis R., Gansmuller A., Sookhareea S., Bosher J.M., Baillie D.L., Labouesse M. LET-413 is a basolateral protein required for the assembly of adherens junctions in Caenorhabditis elegans. Nature Cell Biology 2000, 2:415-422.
23. Liu D., Shi M., Zhang H., Qian L., Yu M., Hu M., Zhang R., Wang T., Han C., Duan H., Guo N. c-Myb regulates cell cycle-dependent expression of Erbin: an implication for a novel function of Erbin. PLoS ONE 2012, 7:e42903.
24. Martin-Belmonte F., Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. Nature Reviews Cancer 2012, 12:23-38.
25. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., Klos K.S., Li P., Monia B.P., Nguyen N.T., Hortobagyi G.N., Hung M.C., Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
26. Nakagawa S., Yano T., Nakagawa K., Takizawa S., Suzuki Y., Yasugi T., Huibregtse J.M., Taketani Y. Analysis of the expression and localisation of a LAP protein, human scribble, in the normal and neoplastic epithelium of uterine cervix. British Journal of Cancer 2004, 90:194-199.
27. Rangwala R., Banine F., Borg J.P., Sherman L.S. Erbin regulates mitogen-activated protein (MAP) kinase activation and MAP kinase-dependent interactions between Merlin and adherens junction protein complexes in Schwann cells. Journal of Biological Chemistry 2005, 280:11790-11797.
28. Shi M., Liu D., Duan H., Qian L., Wang L., Niu L., Zhang H., Yong Z., Gong Z., Song L., Yu M., Hu M., Xia Q., Shen B., Guo N. The beta2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Research and Treatment 2011, 125:351-362.
29. Shi M., Zhao M., Hu M., Liu D., Cao H., Qian L., Yang Z., Hu Y., Yu M., Yang S., Ma Y., Guo N. beta2-AR-induced Her2 transactivation mediated by Erbin confers protection from apoptosis in cardiomyocytes. International Journal of Cardiology 2012, 10.1016/jijcard.2012.04.093.
30. Spector N.L., Blackwell K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology 2009, 27:5838-5847.
31. Stern H.M. Improving treatment of HER2-positive cancers: opportunities and challenges. Science Translational Medicine 2012, 4:127rv122.
32. Thompson J.E., Thompson C.B. Putting the rap on Akt. Journal of Clinical Oncology 2004, 22:4217-4226.
33. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Reviews Cancer 2002, 2:489-501.
34. Warner D.R., Pisano M.M., Roberts E.A., Greene R.M. Identification of three novel Smad binding proteins involved in cell polarity. FEBS Letters 2003, 539:167-173.
35. Wu M., Pastor-Pareja J.C., Xu T. Interaction between Ras(V12) and scribbled clones induces tumour growth and invasion. Nature 2010, 463:545-548.
36. Yuan G., Qian L., Shi M., Lu F., Li D., Hu M., Yu M., Shen B., Guo N. HER2-dependent MMP-7 expression is mediated by activated STAT3. Cellular Signalling 2008, 20:1284-1291.
37. Zhan L., Rosenberg A., Bergami K.C., Yu M., Xuan Z., Jaffe A.B., Allred C., Muthuswamy S.K. Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell 2008, 135:865-878.
38. Zhang H., Yu M., Hu M., Qian L., Chen L., Shi M., Shen B., Guo N. Overexpression, refolding, purification of Erbin PDZ domain from Escherichia coli and preparation of its polyclonal antibody. Preparative Biochemistry and Biotechnology 2008, 38:282-293.